Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab Journal Article

   


Authors: Chapman, P. B.; Jayaprakasam, V. S.; Panageas, K. S.; Callahan, M.; Postow, M. A.; Shoushtari, A. N.; Wolchok, J. D.; Betof Warner, A.
Article Title: Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
Abstract: Background In melanoma patients who progress after prior ipilimumab/nivolumab (ipi/nivo) combination immunotherapy, there is no information regarding the risks and benefits of reinduction ipi/nivo. Methods This was a retrospective review of 26 melanoma patients treated at Memorial Sloan Kettering Cancer Center (MSKCC) since 2012 who received reinduction ipi/nivo at least 6 months following completion of an initial course of ipi/nivo. We collected data on demographics, genetics, immune-related adverse events (irAEs), best overall responses (BORs), time to treatment failure (TTF) and overall survival (OS). Results The BOR rate (complete response+partial response) was 74% (95% CI 52% to 90%) after the first course of ipi/nivo but only 23% (95% CI 8% to 45%)) after reinduction. Response to reinduction did not correlate with response to the initial course. Among the 16 patients who had an objective response to the first course, only four (25%) responded to reinduction. Of five patients who did not respond to the first course, one responded to reinduction. For all patients, median TTF was 5.3 months after reinduction; TTF was shorter for reinduction than for the first course in 85% of patients. Median OS from reinduction was 8.4 months; estimated 2-year OS was 18%. Although reinduction was associated with fewer irAEs than the initial course of ipi/nivo (58% of patients vs 85% of patients in the initial course), eight (31%) patients experienced at least one new irAE after the second course. Conclusions BOR rate and TTF were markedly less favorable after reinduction with ipi/nivo than after the initial course of ipi/nivo. Reinduction ipi/nivo was associated with frequent irAEs although less frequent than for the initial course. © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Keywords: melanoma; immunotherapy
Journal Title: Journal for ImmunoTherapy of Cancer
Volume: 9
Issue: 10
ISSN: 2051-1426
Publisher: Biomed Central Ltd  
Date Published: 2021-10-01
Start Page: e003395
Language: English
DOI: 10.1136/jitc-2021-003395
PROVIDER: scopus
PMCID: PMC8549669
PUBMED: 34702752
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85118582110&doi=10.1136%2fjitc-2021-003395&partnerID=40&md5=b5f3b403340fd12e0c42faee4d37d2cd
Notes: Article -- Export Date: 1 December 2021 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Jedd D Wolchok
    905 Wolchok
  2. Michael Andrew Postow
    361 Postow
  3. Paul Chapman
    326 Chapman
  4. Margaret Kathleen Callahan
    197 Callahan
  5. Katherine S Panageas
    512 Panageas
  6. Alexander Noor Shoushtari
    244 Shoushtari
  7. Allison Betof Warner
    76 Betof Warner
  8. Vetri Sudar Jayaprakasam
    25 Jayaprakasam
Related MSK Work